Stereotaxis, Inc.

NYSE American STXS

Stereotaxis, Inc. Market Capitalization on January 14, 2025: USD 175.39 M

Stereotaxis, Inc. Market Capitalization is USD 175.39 M on January 14, 2025, a 18.03% change year over year. Market capitalization represents total company value in stock market; higher suggests larger, more established company.
  • Stereotaxis, Inc. 52-week high Market Capitalization is USD 261.27 M on April 05, 2024, which is 48.97% above the current Market Capitalization.
  • Stereotaxis, Inc. 52-week low Market Capitalization is USD 142.57 M on June 26, 2024, which is -18.71% below the current Market Capitalization.
  • Stereotaxis, Inc. average Market Capitalization for the last 52 weeks is USD 181.52 M.
Key data
Date Market Capitalization Share Price Price to Earnings Ratio (P/E) Price to Sales Ratio (P/S)
Market news
Loading...
NYSE American: STXS

Stereotaxis, Inc.

CEO Dr. David Leo Fischel C.A.I.A., C.F.A., C.P.A., M.B.A.
IPO Date Aug. 12, 2004
Location United States
Headquarters 710 North Tucker Boulevard
Employees 122
Sector Technology
Industries
Description

Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. Its robotic magnetic navigation (RMN) systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. The company also provides Odyssey, a real-time information solution to manage, control, record, and share procedures across networks; and Stereotaxis Imaging Model S X-ray system, a single-plane full-power x-ray system, including c-arm, powered table, motorized boom, and large high-definition monitors for a robotic interventional operating room. In addition, it offers disposables and other accessories, such as QuikCAS automated catheter advancement disposables for the remote advancement of electrophysiology catheters; and CARTO RMT navigation and ablation system, CELSIUS RMT, NAVISTAR RMT, NAVISTAR RMT DS, NAVISTAR RMT THERMOCOOL, and CELSIUS RMT THERMOCOOL irrigated tip diagnostic/ablation steerable tip catheters. Further, the company provides Vdrive, a system that offers navigation and stability for the diagnostic and therapeutic devices designed to improve interventional procedures; and V-Loop, V-Sono, and V-CAS disposable components. Stereotaxis, Inc. markets its products through direct sales force, distributors, and sales agents. The company has a strategic collaboration with Osypka AG to develop a magnetic ablation catheter using Stereotaxis' robotic technology. Stereotaxis, Inc. was incorporated in 1990 and is headquartered in Saint Louis, Missouri.

Similar companies

EDAP

EDAP TMS S.A.

USD 2.02

-2.42%

ATRC

AtriCure, Inc.

USD 34.69

0.87%

ANGO

AngioDynamics, Inc.

USD 11.80

-5.30%

ARAY

Accuray Incorporated

USD 2.20

-1.79%

StockViz Staff

January 15, 2025

Any question? Send us an email